Dan --- from the Zengen website (Zengen.com), see the bio for Charles Hensley. It appears that Biodelivery Tech was ACQUIRED by Zengen in March 2000!! I thought GUMM had the right to purchase the remaining 40% of Gel Tech that it doesn't already own --- maybe it'll have to be purchased from Zengen, the new owner of BDT. rli
Charles B. Hensley, Ph.D.
President, Director
Dr. Hensley has been President and a Director of
Zengen since October 1999. Prior to joining Zengen,
Dr. Hensley was Chief of Research and Scientific
Affairs at Gel Tech, LLC, a joint venture between
Biodelivery Technologies, Inc., and Gum Tech
International, a Nasdaq publicly traded company.
From 1997 to 1999, Dr. Hensley served as Chairman
of Biodelivery Technologies, Inc., which was acquired
by Zengen in March 2000. From 1994 to 1997, Dr.
Hensley served as Chairman of Biotem
Cytotechnologies, a research company specializing in
natural therapeutics. Dr. Hensley received his
bachelor's of science degree in Zoology from the
University of Oklahoma. Dr. Hensley received his Ph.
D. in Physiology and Biophysics from the University of
Southern California and served his postdoctoral
fellowship at the University of Southern California
where he specialized in the regulation of gene
expression in the myocardium. Dr. Hensley has held
various teaching positions at University of Southern
California and University of California, Riverside. |
